| review article | Q7318358 |
| scholarly article | Q13442814 |
| P50 | author | Annabel E. Barber | Q59879010 |
| P2093 | author name string | Patrizio Tatti | |
| Adriano Longobardi | |||
| Leonardo Masselli | |||
| Patrizia Di Mauro | |||
| P2860 | cites work | Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study | Q22242096 |
| Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group | Q27860882 | ||
| The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group | Q27861088 | ||
| Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes | Q29547541 | ||
| 10-year follow-up of intensive glucose control in type 2 diabetes | Q29615973 | ||
| Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage | Q29616101 | ||
| Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group | Q29617736 | ||
| The pathobiology of diabetic complications: a unifying mechanism | Q29617766 | ||
| Glucose control and vascular complications in veterans with type 2 diabetes | Q29619213 | ||
| Effect of ruboxistaurin on visual loss in patients with diabetic retinopathy | Q30823864 | ||
| Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy | Q30837772 | ||
| The efficacy of octreotide in the therapy of severe nonproliferative and early proliferative diabetic retinopathy: a randomized controlled study | Q30881124 | ||
| Evidence that upregulation of serum IGF-1 concentration can trigger acceleration of diabetic retinopathy | Q31918268 | ||
| Antioxidant therapy: a new pharmacological approach in shock, inflammation, and ischemia/reperfusion injury | Q31921143 | ||
| Antioxidant vitamins and prevention of cardiovascular disease: epidemiological and clinical trial data | Q32062421 | ||
| Inhibition of intraocular neovascularization caused by retinal ischemia in pigs by PKCbeta inhibition with LY333531. | Q32145246 | ||
| Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial. | Q33305306 | ||
| The Effect of Pregnancy on the Natural Course of Diabetic Retinopathy | Q51650855 | ||
| Multiple factors in the prediction of risk of proliferative diabetic retinopathy. | Q52945657 | ||
| Studies on diabetic retinopathy. 3. Influence of diabetes on intramural pericytes. | Q53785619 | ||
| The Wisconsin Epidemiologic Study of Diabetic Retinopathy. XIII. Relationship of serum cholesterol to retinopathy and hard exudate | Q68018610 | ||
| Serum cholesterol in Wisconsin epidemiologic study of diabetic retinopathy | Q68074230 | ||
| Is blood pressure a predictor of the incidence or progression of diabetic retinopathy? | Q69553999 | ||
| The Wisconsin epidemiologic study of diabetic retinopathy. III. Prevalence and risk of diabetic retinopathy when age at diagnosis is 30 or more years | Q70330516 | ||
| Increased incidence of retinopathy in diabetics with elevated blood pressure. A six-year follow-up study in Pima Indians | Q72126211 | ||
| Effects of aldose reductase inhibition with tolrestat on diabetic retinopathy in a six months double blind trial | Q72533630 | ||
| Correlation of diacylglycerol level and protein kinase C activity in rat retina to retinal circulation | Q72603233 | ||
| Serious retinopathy in a diabetic clinic: prevalence and therapeutic implications | Q72642213 | ||
| Advanced glycation end products induce blood-retinal barrier dysfunction in normoglycemic rats | Q73080753 | ||
| Effect of lisinopril on progression of retinopathy in normotensive people with type 1 diabetes. The EUCLID Study Group. EURODIAB Controlled Trial of Lisinopril in Insulin-Dependent Diabetes Mellitus | Q74058742 | ||
| Standards of medical care in diabetes--2010. | Q33554238 | ||
| Effects of medical therapies on retinopathy progression in type 2 diabetes | Q33620031 | ||
| Pathogenetic potential of leukocytes in diabetic retinopathy | Q33887334 | ||
| Aldose reductase gene polymorphisms and diabetic retinopathy susceptibility. | Q34016102 | ||
| The role of protein kinase C in the development of the complications of diabetes | Q34064170 | ||
| Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders | Q34292807 | ||
| Aldose reductase (AC)n gene polymorphism and susceptibility to diabetic retinopathy in Type 2 diabetes in Caucasians. | Q34399836 | ||
| Vascular effects of acute hyperglycemia in humans are reversed by L-arginine. Evidence for reduced availability of nitric oxide during hyperglycemia | Q34421962 | ||
| Advanced glycation end products, their receptors and diabetic angiopathy | Q34428832 | ||
| Systemic considerations in the management of diabetic retinopathy | Q34434932 | ||
| A new view of diabetic retinopathy: a neurodegenerative disease of the eye. | Q35092253 | ||
| New Insights on Oxidative Stress and Diabetic Complications May Lead to a “Causal” Antioxidant Therapy | Q35115544 | ||
| The renin-angiotensin system influences ocular endothelial cell proliferation in diabetes: transgenic and interventional studies | Q35748852 | ||
| Screening for subclinical complications in young type 1 diabetic patients: experience acquired in Brussels. | Q36377728 | ||
| Intravitreous anti-VEGF for diabetic retinopathy: hopes and fears for a new therapeutic strategy | Q37135388 | ||
| Vascular endothelial growth factor and diabetic complications | Q37302047 | ||
| Association of A1C and fasting plasma glucose levels with diabetic retinopathy prevalence in the U.S. population: Implications for diabetes diagnostic thresholds | Q37400796 | ||
| Influence of pericytes on capillary endothelial cell growth | Q38705187 | ||
| Early functional and morphologic vascular renal consequences of the diabetic state | Q39808753 | ||
| Endothelial nuclear factor-kappa B and the initiation of the atherosclerotic lesion | Q40909179 | ||
| Effect of pregnancy on progression of diabetic retinopathy | Q41779547 | ||
| Beneficial effects of alpha-lipoic acid and ascorbic acid on endothelium-dependent, nitric oxide-mediated vasodilation in diabetic patients: relation to parameters of oxidative stress | Q43652975 | ||
| An aldose reductase inhibitor reverses early diabetes-induced changes in peripheral nerve function, metabolism, and antioxidative defense | Q43800088 | ||
| The effect of a growth hormone receptor antagonist drug on proliferative diabetic retinopathy | Q43815650 | ||
| Aldose reductase inhibitor fidarestat prevents retinal oxidative stress and vascular endothelial growth factor overexpression in streptozotocin-diabetic rats. | Q44329008 | ||
| Diabetic retinopathy: contemporary prevalence in a well-controlled population | Q44563979 | ||
| Diabetes trends in the U.S.: 1990-1998. | Q44590624 | ||
| Long-term follow-up of patients who underwent yttrium-90 pituitary implantation for treatment of proliferative diabetic retinopathy | Q44669997 | ||
| PPARalpha activators inhibit vascular endothelial growth factor receptor-2 expression by repressing Sp1-dependent DNA binding and transactivation | Q44698975 | ||
| Advanced glycation end-products increase monocyte adhesion to retinal endothelial cells through vascular endothelial growth factor-induced ICAM-1 expression: inhibitory effect of antioxidants. | Q44799753 | ||
| Dyslipidaemia and microvascular disease in the retina | Q45053159 | ||
| A prospective study of serum lipids and risk of diabetic macular edema in type 1 diabetes | Q45124393 | ||
| Suppression of retinal neovascularization by the iNOS inhibitor aminoguanidine in mice of oxygen-induced retinopathy | Q46081402 | ||
| The effects of an aldose reductase inhibitor on the progression of diabetic retinopathy | Q46165988 | ||
| UKPDS and the legacy effect. | Q46325188 | ||
| Effect of candesartan on progression and regression of retinopathy in type 2 diabetes (DIRECT-Protect 2): a randomised placebo-controlled trial | Q46341489 | ||
| Retrospective analysis of rosiglitazone and macular oedema in patients with type 2 diabetes mellitus | Q46648460 | ||
| P275 | copyright license | Creative Commons Attribution-NonCommercial 3.0 Unported | Q18810331 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | eye disease | Q3041498 |
| P304 | page(s) | 1291-1298 | |
| P577 | publication date | 2010-11-15 | |
| P1433 | published in | Clinical Ophthalmology | Q5133782 |
| P1476 | title | Prevention of diabetic eye disease: the commonest cause of blindness in individuals younger than 65 years | |
| P478 | volume | 4 |
Search more.